Oral ethanol-reinforced responding in rhesus monkeys: Effects of opioid antagonists selective for the μ-, κ-, or δ-receptor

Alcoholism: Clinical and Experimental Research

Volumn 22, Issue 8, 1998, Pages 1634-1639

  Williams, Keith L ^b   Woods, James H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alcohol; Drinking; Naltrexone; Opioids; Receptors

Indexed keywords

ALCOHOL; CLOCINNAMOX; DELTA OPIATE RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY;

EID: 0031762121     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-0277.1998.tb03960.x     Document Type: Article

References (34)

1. O'Malley S, Jaffe A, Chang G, Shottenfeld R, Meyer R, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49:881-887, 1992
2. Volpicelli J, Alterman A, Hayashida M, O'Brien C: Naltrexone in treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880, 1992
3. Volpicelli J, Watson N, King A, Sherman C, O'Brien C: Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 152:613-615, 1995
4. Gianoulakis C, de Waele JP: Genetics of alcoholism: Role of endogenous opioid system. Metab Brain Dis 9:105-131, 1994
5. Ulm R, Volpicelli J, Volpicelli L: Opiates and alcohol self-administration in animals. J Clin Psychiatry 56:5-14, 1995
6. Williams K, Winger G, Pakarinen E, Woods J: Naltrexone reduces ethanol- and sucrose-reinforced responding in rhesus monkeys. Psychopharmacology (in press)
7. Froehlich J, Harts J, Lumeng L, Li T-K: Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 35:385-390, 1990
8. Childers S, Creese I, Snowman A, Snyder S: Opiate receptor binding affected differentially by opiates and opioid peptides. Eur J Pharmacol 55:11-18, 1979
9. Leander J: A kappa opioid effect: Increased urination in the rat. J Pharmacol Exp Ther 224:89-93, 1983
10. Paterson S, Corbett A, Gillan M, Kosterlitz H, McKnight A, Robson L: Radioligands for probing opioid receptors. J Recept Res 4:143-154, 1984
11. Froehlich J, Zweifel M, Harts J, Lumeng L, Li T-K: Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology 103:467-472, 1991
12. Krishnan-Sarin S, Jing S, Kurtz M, Portoghese P, Li T-K, Froehlich J: The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology 120:177-185, 1995
13. Hyytia P: Involvement of μ-opioid receptors in alcohol drinking by alcohol preferring AA rats. Pharmacol Biochem Behav 45:697-701, 1993
14. Krishnan S, Portoghese P, Li T-K, Froehlich JC: Evidence for mu opioid receptor involvement in alcohol drinking. Alcohol Clin Exp Res 18:480, 1994
15. Ward S, Portoghese P, Takemori A: Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J Pharmacol Exp Ther 220:494-498, 1982
16. Comer S, Burke T, Lewis J, Woods J: Clocinnamox: A novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther 262:1051-1056, 1992
17. Butelman E, Negus S, Lewis J, Woods J: Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys. Psychopharmacology 123:320-324, 1996
18. Zernig G, Butelman E, Lewis J, Walker E, Woods J: In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J Pharmacol Exp Ther 269:57-65, 1994
19. Burke T, Woods J, Lewis J, Medzihradsky F: Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther 271:715-721, 1994
20. 3H]DAMGO binding in rats. Eur J Pharmacol 337:27-34, 1997
21. Takemori A, Ho B, Naeseth J, Portoghese P: Nor-Binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 246:255-258, 1988
22. Butelman E, Negus S, Al Y, de Costa R, Woods J: Kappa opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J Pharmacol Exp Ther 267:1269-1276, 1993
23. Negus S, Butelman E, Chang K, DeCosta B, Winger G, Woods J: Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys. J Pharmacol Exp Ther 270:1025-1034, 1994
24. 2 analysis in rhesus monkeys. J Pharmacol Exp Ther 285:518-526, 1998
25. Meisch R, Henningfield J, Thompson T: Establishment of ethanol as a reinforcer for rhesus monkeys via the oral route: Initial results. Adv Exp Med Biol 59:323-342, 1975
26. Zernig G, Lewis J, Woods J: Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: Comparison with effect on opioid agonist-mediated antinociception. Psychopharmacology 129:233-242, 1997
27. France C, Gerak L: Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther 270:992-999, 1994
28. Cooper S, Jackson A, Kirkham T: Endorphins and food intake: Kappa opioid receptor agonists and hyperphagia. Pharmacol Biochem Behav 23:889-901, 1985
29. Arjune D, Bodnar R: Suppression of nocturnal, palatable and glucoprivic intake in rats by the κ-opioid antagonist, nor-binaltorphamine. Brain Res 534:313-316, 1990
30. Katafuchi T, Hattori Y, Nagatomo I, Koizumi K: Kappa-opioid antagonist strongly attenuates drinking of genetically polydipsic mice. Brain Res 546:1-7, 1991
31. Jewett D, Woods J: Nor-binaltrophimine: An ultra-long acting kappa-opioid antagonist in pigeons. Behav Pharmacol 6:815-820, 1995
32. Woods J, Winger G, France C: Use of in vivo apparent pA2 analysis in assessment of opioid abuse liability. Trends Pharmacol Sci 13:282-285, 1992
33. Endoh T, Koike H, Matsuura H, Nagase H: Nor-Binaltorphimine (nor-BNI): A potent and selective kappa-opioid receptor antagonist with ultra-long-lasting activity in vivo, in Van Ree J, Mulder A, Wiegant V, van Wimersma Greidanus T (eds): New Leads in Opioid Research. Amsterdam, The Netherlands, Elsevier Science Publishers, 1990, pp 82-83
34. Krishan-Sarin S, Portoghese P, Li T-K, Froehlich J: The delta2 opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav 52:153-159, 1995